Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813444 | 0.87 | GRIN2D (0.53) | PARP15PARP10PARP2GRIN2DGRIN3B | |
| SCHEMBL796332 | 0.86 | GRIN2D (0.55) | PARP15PARP10PARP2GRIN2DGRIN3B | |
| SCHEMBL13519209 | 0.85 | MEN1 (0.56) | — | |
| SCHEMBL5207764 | 0.85 | POLB (0.56) | PARP15PARP10PARP2 | |
| SCHEMBL216252 | 0.85 | F10 (0.47) | PARP15PARP10PARP2F2GRIN2D | |
| SCHEMBL20420997 | 0.84 | PARP15 (0.47) | PARP15PARP10PARP2 | |
| SCHEMBL3090147 | 0.84 | SIGMAR1 (0.62) | PARP15PARP10PARP2 | |
| SCHEMBL19610285 | 0.83 | PARP15 (0.46) | PARP15PARP10PARP2GRIN2DGRIN3B | |
| SCHEMBL5687559 | 0.83 | PARP15 (0.46) | PARP15PARP10PARP2 | |
| SCHEMBL20421066 | 0.83 | PARP15 (0.46) | PARP15PARP10PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325889-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3897635-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Celgene Corporation (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20200199074-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| WO-2020132016-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | PARP15 1965/4885PARP10 2012/4885PARP2 1016/4885 |
| US-11325889-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | PARP15 780/4885PARP10 853/4885PARP2 406/4885 |
| US-20200199074-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | PARP15 780/4885PARP10 853/4885PARP2 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.